The fibrinogen to albumin ratio, as an inflammatory serum biomarker, has been identified in several studies as a predictor of poor outcome and adverse events in patients with cardiovascular diseases, cancer, sepsis, and stroke [18,19,20,21,22,23,24,25,26,27]. This evidence concerns the gene ALB and cancer.